Digital Era of Pharmaceutical R&D

The level of #innovation in #pharmaceutical and #biotechnology R&D over the last few decades has been outstanding. We see that while disease management has radically changed and innovated, many experts in the industry as well as investors admit that the industry is slow to adopt to the new digital era and open up to the use of advanced technology to help with the #digitalization of #clinical research. The goal of a biotechnology company is to develop innovative medicines that demonstrate differentiated treatment opportunities while reducing the cost and time to market and maximizing return on investment. Recent Deloitte's analysis of return on pharmaceutical R&D investments for a cohort of 12 large biopharma companies shows a sustained decline from 10.1 percent in 2010 to 3.2 percent in 2017. Fortunately, new digital #technologies are coming out and aim to optimize the clinical development process, and more broadly the entire R&D value chain.